<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00997685</url>
  </required_header>
  <id_info>
    <org_study_id>ML22298</org_study_id>
    <nct_id>NCT00997685</nct_id>
  </id_info>
  <brief_title>Evaluate Efficacy and Safety of XELOX in Potentially Resectable Liver Metastasis From Colorectal Cancer(CRC)</brief_title>
  <official_title>A Single Arm, Open-label Phase II Study to Evaluate the Efficacy and Safety of Capecitabine Plus Oxaliplatin (XELOX) in the Peri-operative Treatment of Patients With Potentially Resectable Liver Metastasis From Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guangdong General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Guangdong General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single arm, open-label phase II study to evaluate the efficacy and safety of
      Capecitabine plus oxaliplatin (XELOX) in the peri-operative treatment of patients with
      potentially resectable liver metastasis from colorectal cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To investigate the progression free survival (PFS) advantage of Xeloda plus oxaliplatin in
      the peri-operative treatment of potential resectable metastatic colorectal cancer
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>November 2009</start_date>
  <completion_date type="Anticipated">October 2015</completion_date>
  <primary_completion_date type="Anticipated">October 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To investigate the progression free survival (PFS) advantage of Xeloda plus oxaliplatin in the peri-operative treatment of potential resectable metastatic colorectal cancer</measure>
    <time_frame>3.6 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To investigate the response rate</measure>
    <time_frame>3.6 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the R0 resection rate</measure>
    <time_frame>3.6 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the safety profile of XELOX peri-operative treatment</measure>
    <time_frame>3.6 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Potentially Resectable Liver Metastasis From CRC</condition>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Capecitabine plus oxaliplatin，mCRC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine plus oxaliplatin</intervention_name>
    <description>Xeloda: 1000mg/m2 bid, d1-14, q3w, Oxaliplatin:130mg/m2 d1, q3w,
4 pre-operative cycles, 4 post-operative cycles</description>
    <arm_group_label>Capecitabine plus oxaliplatin，mCRC</arm_group_label>
    <other_name>XELOX</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age of 18 and 65

          -  Histologically confirmed colorectal cancer and two methords of imaging detection
             confirmed liver metastasis

          -  Potentially curable by resection, as determined by a surgeon with hepatic surgery
             expertise

          -  No evidence of extrahepatic disease by chest x-ray or CT scan of the chest, abdomen,
             and pelvis

          -  Patients with adequate hepative, renal and bone marrow function

          -  Signed written informed consent

        Exclusion Criteria:

          -  Pregnant or nursing patients (fertile patients must use effective contraception)

          -  Other malignancy within the past 5 years except completely resected nonmelanoma skin
             cancer or carcinoma in situ of the cervix

          -  Preexisting grade 2 or greater peripheral neuropathy

          -  Concurrent uncontrolled illness

          -  Ongoing or active infection

          -  Psychiatric illness or social situation that would preclude study compliance

          -  Less than 6 months since prior adjuvant fluorouracil-based chemotherapy

          -  Prior chemotherapy for liver metastasis

          -  Prior oxaliplatin for colorectal cancer

          -  Prior or concurrent hepatic artery infusion chemotherapy for metastatic disease

          -  Prior or concurrent radiotherapy for metastatic disease

          -  Prior or concurrent radiofrequency ablation for metastatic disease

          -  concurrent treatment with any other anti-cancer therapy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Feng Lin</last_name>
    <role>Principal Investigator</role>
    <affiliation>Guangdong General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Feng Lin, Dr</last_name>
    <phone>+8613903018609</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yong Li, Dr</last_name>
    <phone>+8613822177479</phone>
    <email>yongyongsmart@yahoo.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Guangdong General Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yong Li, Dr</last_name>
      <email>yongyongsamrt@yahoo.cn</email>
    </contact>
    <investigator>
      <last_name>Feng Lin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 18, 2009</study_first_submitted>
  <study_first_submitted_qc>October 18, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 19, 2009</study_first_posted>
  <last_update_submitted>October 18, 2009</last_update_submitted>
  <last_update_submitted_qc>October 18, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 19, 2009</last_update_posted>
  <responsible_party>
    <name_title>Institutions of national drug clinical trials</name_title>
    <organization>Guangdong General Hospital</organization>
  </responsible_party>
  <keyword>XELOX</keyword>
  <keyword>potentially resectable liver metastasis from CRC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neoplasms, Second Primary</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

